Zgierz, Poland Clinical Trials

A listing of Zgierz, Poland clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 200 clinical trials
Featured trial
Building Community and Research Engagement among Sexual and Gender Minority Older Adults at Risk for Alzheimer’s Disease and Related Dementias

The RISE Registry - (Research Inclusion Supports Equity) is a national effort to address the needs of 18+ LGBTQIA+ who: Have memory concerns or a memory loss diagnosis such as Alzheimer's disease or related dementia (ADRD) Are helping care for someone with memory loss or a memory loss diagnosis Individuals …

alzheimer's disease
Online studies
dementia
Accepts healthy volunteers
Online Study Center
(online study) Contact site
  • 19 views
  • 24 Jan, 2023
  • 1 location
  • Online study
Featured trial
Alzheimer's Disease Family Based Study (AD FBS)

This study is looking for people who have Alzheimer’s or a related dementia, and also have family members who have Alzheimer’s. The study is interested in the genetics of Alzheimer’s risk.

dementia
Online studies
Accepts healthy volunteers
University of Texas Southwestern Medical Center*
(online study) Contact site
  • 2313 views
  • 27 Jan, 2023
  • 1 location
  • Online study
Featured trial
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im. M. Kopern /Id# 221161
 (9.1 away) Contact site
  • 879 views
  • 23 Oct, 2022
  • +225 other locations
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.

lenalidomide
marginal zone lymphoma
rituximab
follicular lymphoma
Uniwersytet Medyczny W Lodzi - Klinika Hematologii
 (8.9 away) Contact site
  • 5 views
  • 27 Oct, 2022
  • +197 other locations
Featured trial
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304) (POD1UM-304)

The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).

Centrum Terapii Wspolczesnej J.M. Jasnorzewska Sp. Komandytowo-Akcyjna
 (6.2 away) Contact site
  • 25 views
  • 19 Dec, 2022
  • +119 other locations
Featured trial
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma

This is a parallel, treatment, Phase 2, double-blind, 2 arm, 12-week Proof of Concept (PoC) study with 2 staggered cohorts (2 arms in each cohort) that is designed to assess the efficacy, safety, and tolerability of rilzabrutinib in adult participants (aged 18-70 years) with moderate-to-severe asthma who are not well …

Investigational Site Number :6160001
 (6.7 away) Contact site
  • 5 views
  • 06 Jan, 2023
  • +22 other locations
Featured trial
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients (EVEREST)

Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives To evaluate the efficacy of dupilumab in improving CRSwNP symptoms at Week 24 compared to omalizumab To evaluate the efficacy of dupilumab in improving lung function at …

Investigational Site Number :6160007
 (6.5 away) Contact site
  • 42 views
  • 26 Jan, 2023
  • +68 other locations
Featured trial
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. Part 2 is an optional long term extension study for …

early parkinson's
Lodzkie Centrum Osteoporozy SOMED
 (7.1 away) Contact site
  • 75 views
  • 26 Jan, 2023
  • +74 other locations
Featured trial
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

lung metastases
advanced lung cancer
docetaxel
KRAS
recurrent non-small cell lung cancer
Mirati Research Site
 (7.3 away) Contact site
  • 37 views
  • 27 Dec, 2022
  • +201 other locations
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Centrum Terapii Wspolczesnej J.M.Jasnorzewska Spolka Komandytowo-Akcyjna
 (6.2 away) Contact site
  • 21 views
  • 15 Oct, 2022
  • +653 other locations